Website CV Paper
Fields
Industrial Organization, Health, Labor
Job market paper
When Payers Intervene: Insurer Restrictions, Physician Expertise, and Cost Control
Insurers use utilization management (UM), such as prior authorization and step therapy, to restrict access to high-cost prescription drugs. UM lets insurers rein in physicians who do not fully internalize drug costs, but it can override physicians' private information about which drugs suit which patients and burden them with administrative hassle. Because UM shifts demand, it also affects the prices insurers negotiate with manufacturers. I develop and estimate a structural model of physician learning and insurer–manufacturer bargaining for antidiabetic drugs in Medicare Part D. Physicians learn quickly about patient-specific drug effectiveness, so UM mainly deters prescriptions for marginal patients: it lowers realized patient–drug match value by only 0.15%, while physicians bear hassle costs on 4.6% of prescriptions. UM lowers total spending by 8.4%, and 42% of that comes from equilibrium prices: the threat of UM holds down negotiated prices for many drugs, even where it is not imposed. Physician-side frictions account for most of the gap from efficient drug allocation, but eliminating UM's administrative burden also requires addressing insurer-side factors such as limited bargaining power.